Document is current

Article History

Accepted: 9 February 2025

First Online: 19 March 2025

Declarations

:

: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

: M.A. has received research grant support from Amryt Pharmaceutical, Amgen, IONIS, Akcea Therapeutics, Daiichi-Sankyo, Novartis, Pfizer, and Regeneron; served as a consultant for Amgen, Akcea Therapeutics, Daiichi-Sankyo, and Ultragenyx; and received fees for lecturing, congress participation, and advisory board participation from Amgen, Amryt Pharmaceutical, Daiichi-Sankyo, Regeneron, Sanofi, Amarin, and Ultragenyx. L.D. has received personal fees for public speaking or consultancy or grant support from Amryt Pharmaceutical, Akcea Therapeutics, SOBI, AuroraBiopharma, Novartis, Amarin, Daiichi-Sankyo, Bayer, and Sandoz. S.B. has received personal fees for public speaking from SOBI; retains stock options in Eli Lilly, UnitedHealth, Novo Nordisk, Merck, and Thermo Fisher Scientific; and received grants for meeting participation from Novartis. D.T. has received personal fees for public speaking from SOBI. C.M., A.D.C., D.C., I.M., M.C., J.C., I.A., S.C., and G.S. have no competing interests.

: D.T. and L.D. were primarily responsible for the conceptualization, methodology, revision of selected articles, and writing of the original draft. L.D. supervised the project. S.B., A.D.C., and I.M. critically revised the manuscript and contributed to the analysis of pharmacokinetic and pharmacodynamic aspects. D.C., as a pharmacist, reviewed the technical aspects related to the medications and critically revised the manuscript. C.M., M.C., J.C., I.A., S.C., and G.S. extensively researched the literature, assisted in reviewing the studies and the selection process, and critically revised the manuscript. M.A. reviewed the selected literature and contributed to the final organization of the manuscript. All authors reviewed and approved the final version of the manuscript

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.